IC-Green (ICG)

Phase 2Small molecule

SSt. Joseph's Healthcare Hamilton

IC-Green (ICG) is one of 2 small molecule programs targeting Indocyanine Green. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Indocyanine GreenRecruiting

Indocyanine GreenPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Indocyanine Green

#DrugCompanyPhaseTrials

IC-Green

PProvepharm SAS

Approved

21 2

IC-Green (ICG)

SSt. Joseph's Healthcare Hamilton

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Indocyanine Green

NCT03953144

Clinical

Trials by Indication[1]

Indocyanine Green1 trial

Synapse 3D With Intravascular Indocyanine Green

Recruiting·SSt. Joseph's Healthcare Hamilton·Phase 1/2·NCT03953144·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IC-Green (ICG). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IC-Green (ICG) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IC-Green (ICG). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Joseph's Healthcare Hamilton company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSt. Joseph's Healthcare Hamilton

IC-Green (ICG)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Indocyanine Green1 trial

References

Drug Info

Quick Facts

Related News